Shugeng Gao

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 13

Top Venues

BMC medicine

Journal of translational medicine

Clinical epigenetics

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Bolun Zhou, Ruochuan Zang, Peng Song, Moyan Zhang, Fenglong Bie, Guangyu Bai, Yuan Li, Qilin Huai, Yuning Han, Shugeng Gao
Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study. Journal of translational medicine 21 (1) (2023)
Fenglong Bie, Zhijie Wang, Yulong Li, Wei Guo, Yuanyuan Hong, Tiancheng Han, Fang Lv, Shunli Yang, Suxing Li, Xi Li, Peiyao Nie, Shun Xu, Ruochuan Zang, Moyan Zhang, Peng Song, Feiyue Feng, Jianchun Duan, Guangyu Bai, Yuan Li, Qilin Huai, Bolun Zhou, Yu S Huang, Weizhi Chen, Feng-Wei Tan, Shugeng Gao
Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization. Nature communications 14 (1) (2023)
Bolun Zhou, Ruochuan Zang, Peng Song, Moyan Zhang, Fenglong Bie, Guangyu Bai, Yuan Li, Qilin Huai, Yuning Han, Shugeng Gao
Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study. Journal of translational medicine 21 (1) (2023)
Yong Li, Aiping Zhou, Shuoyan Liu, Ming He, Keneng Chen, Ziqiang Tian, Yin Li, Jianjun Qin, Zhen Wang, Haiquan Chen, Hui Tian, Yue Yu, Wang Qu, Liyan Xue, Shun He, Shuhang Wang, Fenglong Bie, Guangyu Bai, Bolun Zhou, Zhaoyang Yang, Huiyao Huang, Yan Fang, Benjamin Li, Xiangrong Dai, Shugeng Gao, Jie He
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC. BMC medicine 21 (1) (2023)
Yong Li, Aiping Zhou, Shuoyan Liu, Ming He, Keneng Chen, Ziqiang Tian, Yin Li, Jianjun Qin, Zhen Wang, Haiquan Chen, Hui Tian, Yue Yu, Wang Qu, Liyan Xue, Shun He, Shuhang Wang, Fenglong Bie, Guangyu Bai, Bolun Zhou, Zhaoyang Yang, Huiyao Huang, Yan Fang, Benjamin Li, Xiangrong Dai, Shugeng Gao, Jie He
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC. BMC medicine 21 (1) (2023)
Bolun Zhou, Ruochuan Zang, Peng Song, Moyan Zhang, Fenglong Bie, Guangyu Bai, Yuan Li, Qilin Huai, Yuning Han, Shugeng Gao
Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study. Journal of translational medicine 21 (1) (2023)
Yong Li, Aiping Zhou, Shuoyan Liu, Ming He, Keneng Chen, Ziqiang Tian, Yin Li, Jianjun Qin, Zhen Wang, Haiquan Chen, Hui Tian, Yue Yu, Wang Qu, Liyan Xue, Shun He, Shuhang Wang, Fenglong Bie, Guangyu Bai, Bolun Zhou, Zhaoyang Yang, Huiyao Huang, Yan Fang, Benjamin Li, Xiangrong Dai, Shugeng Gao, Jie He
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC. BMC medicine 21 (1) (2023)
Bolun Zhou, Ruochuan Zang, Peng Song, Moyan Zhang, Fenglong Bie, Guangyu Bai, Yuan Li, Qilin Huai, Yuning Han, Shugeng Gao
Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study. Journal of translational medicine 21 (1) (2023)
Yong Li, Aiping Zhou, Shuoyan Liu, Ming He, Keneng Chen, Ziqiang Tian, Yin Li, Jianjun Qin, Zhen Wang, Haiquan Chen, Hui Tian, Yue Yu, Wang Qu, Liyan Xue, Shun He, Shuhang Wang, Fenglong Bie, Guangyu Bai, Bolun Zhou, Zhaoyang Yang, Huiyao Huang, Yan Fang, Benjamin Li, Xiangrong Dai, Shugeng Gao, Jie He
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC. BMC medicine 21 (1) (2023)
Shuhang Wang, Pei Yuan, Beibei Mao, Ning Li, Jian-Ming Ying, Xiuli Tao, Wei Tang, Lei Zhang, Xiao Geng, Fan Zhang, Qi Xue, Lijia Wu, Henghui Zhang, Shugeng Gao, Jie He
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. NPJ precision oncology 6 (1) (2022)
Zhenlin Yang, He Tian, Lin Li, Chao Li, Jiachen Xu, Fenglong Bie, Ying Chen, Yanhua Tian, Guangyu Bai, Yue Peng, Junhui Yang, Tao Fan, Chu Xiao, Wenchao Liu, Lei Liu, Renda Li, Sijin Sun, Bo Zheng, Fengwei Tan, Jianming Ying, Chunxiang Li, Shugeng Gao, Jie He
PSC subtyping based on TTF-1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies. International journal of cancer 151 (5) (2022)
Fenglong Bie, He Tian, Nan Sun, Ruochuan Zang, Moyan Zhang, Peng Song, Lei Liu, Yue Peng, Guangyu Bai, Bolun Zhou, Shugeng Gao
Comprehensive analysis of PD-L1 expression, tumor-infiltrating lymphocytes, and tumor microenvironment in LUAD: differences between Asians and Caucasians. Clinical epigenetics 13 (1) (2021)
Bolun Zhou, Shugeng Gao
Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma. Cancer immunology, immunotherapy : CII (2021)

Shugeng Gao.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Shugeng Gao